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This study is rooted in the research traditions of cultivation theory, 
construct accessibility, and availability heuristic. Based on a survey with 221 
subjects, this study finds that familiarity with direct-to-consumer (DTC) print 
advertisements for antidepressant brands is associated with inflated 
perceptions of the prevalence and lifetime risk of depression. The study 
concludes that DTC advertising potentially has significant effects on 
perceptions of depression prevalence and risk. Interpersonal experiences with 
depression coupled with DTC advertising appear to significantly predict 
individuals' perceived lifetime risk of depression. The study ultimately 
demonstrates that DTC advertising may play a role in constructing social 
reality of diseases and medicine. The findings strongly suggest that the social 
cognitive effects of DTC advertising are far-reaching, impacting 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Business Ethics, Vol. 79, No. 4 (2008): pg. 379-393. DOI. This article is © Springer and permission has been 
granted for this version to appear in e-Publications@Marquette. Springer does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Springer. 
2 
 
pharmaceutical marketing strategy as well as presenting issues regarding 
public health and the business ethics of advertising drugs to consumers. 
Introduction 
Throughout the 1990s, direct-to-consumer (DTC) advertising 
was one of the most rapidly growing categories of advertising (Davis, 
2000). The U.S. expenditure on DTC advertising increased from $25 
million in 1988 (Morgan and Levy, 1998), to $1.07 billion in 1996, and 
to $2.7 billion in 2002 (U.S. General Accounting Office, 2003). By 
2000, DTC advertising accounted for 15% of the total promotional 
budget in the pharmaceutical industry (Brichacek and Sellers, 2001). 
As a result, DTC advertising constituted 2.5% of the total advertising 
expenditure in the U.S. market in 2000, (NIHCM, 2001) becoming the 
fourth largest consumer-advertising category (Blankenhorn et al., 
2001). 
Promoting prescription drugs directly to consumers has caused a 
nation-wide controversy in the U.S. Opponents of DTC advertising 
argue that it does not provide fair and balanced information about the 
health benefits and risks of a drug (Bell et al., 2000; Coney, 2002). 
They also point out DTC advertising may substantially increase health 
care costs (Findlay, 2001), and adversely affects the doctor-patient 
relationship, as doctors increasingly acquiesce to patients’ requests for 
the drugs they see in DTC advertising (Bell et al., 1999; Mintzes et al., 
2002). In line with these critical viewpoints, in the race for 2004 
Democratic presidential nomination, candidate Howard Dean called for 
a ban on DTC advertising as an element of his 6-point plan to reduce 
prescription drug costs. Two other candidates, Richard Gephardt and 
John Edwards, expressed similar criticisms (Teinowitz, 2003). 
In contrast, proponents argue the content of DTC advertising 
has fair and balanced benefit and risk information and therefore can 
educate consumers about diseases and treatments (Calfee, 2002). 
They further argue DTC advertising can increase awareness of, and 
encourage treatment of, stigmatized and under-diagnosed illnesses 
such as hypercholesterolemia and clinical depression (Calfee, 2002; 
Holmer, 2002). Proponents also points out that DTC advertising 
encourages consumers to search for more information about health 
conditions and treatments (Allison-Ottey et al., 2003; Perri and 
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Dickson, 1988) as well as encourages compliance (Donohue et al., 
2004) and exerts positive influences on the doctor-patient interaction 
(Holmer, 1999). In fact, when candidate Howard Dean's pledge to ban 
DTC advertising received media coverage, Dan Jaffe, executive vice 
president of the Association for National Advertisers, called the 
candidate's plan “a prescription for disaster” and added, “[DTC] 
advertising often provides consumers [with] extremely valuable 
information that can save lives, often avoids serious health problems 
and in so doing often lowers health costs” (Teinowitz, 2003, p. 1). 
Since the “DTC explosion” in the 1990s, researchers have 
explored how DTC advertising is associated with consumer attitudes, 
intention and behavior. For example, Sumpradt et al. (2002) find 
positive attitudes toward DTC advertising predicts willingness to 
discuss advertised drugs with doctors. Beltramini (2006) further finds 
consumers’ perceived believability and comprehension of information 
in DTC advertising predict their plan to consult doctors about health 
issues and request prescriptions for the specific drugs they saw in 
advertising. When doctors refuse to prescribe the requested drugs, 
many consumers are dissatisfied and insist on prescriptions for the 
drugs (Bell et al., 1999; Mehta and Purvis, 2003). In fact, researchers 
(Herzenstein et al., 2005; Kravitz et al., 2005) find consumers’ 
requests for drugs, based on exposure to DTC advertising, increase the 
likelihood of doctors’ prescribing the drugs. At an industry level, Iizuka 
and Jin (2005) find the pharmaceutical industry’s expenditures on DTC 
advertising are associated with consumers’ increased visits to doctors’ 
offices. Zachry et al. (2002) further reveal the DTC expenditures for 
antilipemics significantly predicts the number of diagnoses of 
hyperlipidemia, prescriptions for antilipemics in general, and 
prescriptions for Zocor. Overall, from a marketing perspective DTC 
advertising appears to be successful. 
Despite a large body of research, the current literature on the 
effects of DTC advertising on consumers is limited for a number of 
reasons. The literature is mostly centered around DTC advertising’s 
impact on the way consumers seek health information and interact 
with doctors to get specific drugs, focusing on variables such as 
consumers’ awareness and attitudes regarding DTC advertising, visits 
to doctors’ offices, requests for specific drugs, etc. These are 
important variables and deserve attention. However, a body of 
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literature from social cognition suggests DTC advertising can have 
more far-reaching influences on the way consumers perceive the 
“social reality” of diseases. Elliott (2003), a physician and professor of 
bioethics, suggests as much. Using the case of Paxil, he argues that 
“social reality” can be manipulated to the point where new disease 
categories, such as “social anxiety disorder,” are largely constructed 
by the pharmaceutical industry in an effort to expand drug therapy. 
Elliott (2003) further argues that many drugs advertised to consumers 
promote newly constructed diseases, and thus new disease categories 
rather than promoting public heath. 
Purpose of the study 
Considering the minimal research available on the social 
cognitive effects of DTC advertising, this study focuses on DTC 
advertising’s potential influences on consumers’ perception of 
diseases. Specifically, based on cultivation theory, construct 
accessibility (Sherman and Corty, 1984) and availability heuristic 
(Tversky and Kahneman, 1973), we will explore how consumers’ 
familiarity with DTC advertisements for one specific category of drugs, 
antidepressants, is associated with their perceived social reality of 
depression. We intend to achieve this purpose by testing how 
consumers’ familiarity with DTC print advertisements for 
antidepressants, namely Prozac (produced by Elli Lilly), Paxil CR 
(GlaxoSmithKlein, GSK), Zoloft (Pﬁzer), Wellbutrin XL (GSK) and 
Effexor XR (Wyeth), relates to their perceptions of the prevalence and 
lifetime risk of clinical depression. In addition, we will also explore how 
consumers’ interpersonal experiences with depression, namely 
awareness of their personally meaningful others’ experiences with 
depression, may be associated with their perceptions. 
Of many categories of disease, this study focuses on depression 
for a number of reasons. First, antidepressants, such as Paxil CR and 
Zoloft, have been one of the most heavily advertised prescription drug 
categories in the DTC market (Rosenthal et al., 2002). This may be 
driven by the fact that depression is the most common form of severe 
mood disorders (Altshuler et al., 1998; Weiss and Lonnquist, 1997). 
Second, depression remains a largely under-diagnosed disease 
category (Holmer, 2002). National Institute of Mental Health (NIMH, 
2000) reports, “most people with a depressive illness do not seek 
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treatment” (p. 1). In fact, it would be common for patients to 
experience social stigma related to depression (Elliott, 2003; Holmer, 
2002; Kravitz, 2000). Third, symptoms of depression, such as 
loneliness, feeling of social isolation and worthlessness, and difficulty 
with thinking (American Psychiatric Association, 1994), suggest DTC 
antidepressants advertising is targeted toward a potentially vulnerable 
group of consumers. Hollon (2004) points out special attention is 
required regarding the effects of DTC advertising targeted toward 
consumers suffering psychiatric and neurological illnesses, because 
their decisional capacity may be impaired. 
Last, Donohue and Berndt (2004) reveal pharmaceutical 
companies’ expenditures on DTC antidepressant advertising are 
associated with an overall increase in the number of prescriptions for 
antidepressants. Apart from an increase in the requests for specific 
drugs, they call this expansion of a drug category “a treatment-
expanding effect” (Donohue and Berndt, 2004, p. 124). Given that risk 
perception generally increases intention to seek health information and 
avoid risk behavior and prevent illnesses (Block and Keller, 1998; 
Irwin et al., 1996; Raghubir and Menon, 1998; Siegel et al., 1998), we 
believe that this study, addressing consumers’ prevalence and risk 
perceptions of depression, will add valuable social cognitive insights to 
the treatment-expanding power of DTC advertising; and thus 
implications for public health and business ethics as well as marketing 
strategy. 
Theoretical background 
Cultivation is a theory about the cumulative effects of television 
consumption on viewer conceptions of social reality. Rooted in the 
assumption that television dominates the “symbolic reality of modern 
life”(Gerbner, et al., 1980, p. 5), cultivation theorists posit that the 
amount of television watching is positively related to the degree to 
which people’s beliefs about particular features of social reality mesh 
with the way they are portrayed on television (Potter, 1993). This 
occurs because viewers tend to integrate television information into 
their conceptions of social reality (Potter, 1993). 
Cultivation theorists have explored how television watching 
predicts viewers’ perception of the prevalence of crimes and violence 
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(Gerbner, et al., 1978, 1979, 1980; Hawkins and Pingree, 1980), 
prostitution, alcoholism, and drug use (Shrum and O’Guinn, 1993), as 
well as undesirable sexual behaviors such as teenage pregnancy and 
marital infidelity (Woo and Dominick, 2003). Particularly relevant to 
this study, a group of researchers have applied the theory to consumer 
research. For example, O’Guinn and Shrum (1997) reported exposure 
to soap operas is positively associated with consumers’ perceived 
prevalence of the use of product categories symbolizing affluent 
lifestyles. The association likely occurs because soap operas frequently 
depict affluent lifestyles (O'Guinn and Shrum, 1997) and the television 
world generally over-represents professionals and the upper middle 
class, while under-representing the low class (Lichter et al., 1994). 
The literature on social cognition indicates cultivation theory is 
applicable for this study. Social cognition research has consistently 
found people tend to use little information in making social estimates 
(Taylor and Fiske, 1978; Wyer and Srull, 1989). Researchers (Higgins 
et al., 1977; Roskos-Ewoldsen and Fazio, 1997; Taylor and Fiske, 
1978) propose information, consisting of constructs, most accessible in 
making social estimates tends to be used most frequently, a process 
known as construct accessibility. In making social judgments, these 
judgment-related accessible constructs come to mind as “exemplars” 
of the judgment domain and influence overall social estimates (Shrum, 
2003). Elliott (2003) contends pharmaceutical companies construct 
depression as widespread and common through DTC advertising. We 
propose such construction occurs as DTC advertising increasingly 
disseminates exemplars with which consumers can make social 
judgments. By means of activating a process of construct accessibility 
(Sherman and Corty, 1984), DTC advertising may have a role in the 
social construction of depression. 
Further, more accessible information can also influence social 
estimates through the principle of availability heuristic (Tversky and 
Kahneman, 1973), which posits the more easily people can retrieve 
information, such as relevant examples, from their memory regarding 
a certain feature of social reality, the more prevalent or frequent they 
perceive the phenomenon to be. The ease of retrieving relevant 
information becomes a heuristic that tends to inflate individuals’ 
frequency and prevalence estimates of a phenomenon. We expect that 
accumulated exposure to DTC advertisements for antidepressants will 
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lead individuals to be more familiar with them, and familiarity will 
make consumers’ memory regarding depression and antidepressants 
more accessible. 
A group of researchers (O'Guinn and Shrum, 1997; Shrum and 
Bischak, 2001; Shrum and O'Guinn, 1993) propose the principles of 
construct accessibility and availability heuristic account for the 
psychological processes leading to cultivation effects. They suggest the 
media frequently present relevant exemplars of a feature of social 
reality, making these exemplars highly accessible. Consumers 
comfortably make social estimates partly under the influence of these 
exemplars, and the ease of retrieval of the exemplars tends to drive 
up their social estimates (Shrum and O'Guinn, 1993). Similar to 
television shows, advertising messages can function as a source of 
information that can be stored in people’s memory and retrieved for 
social judgments. For example, studies reveal consumers’ exposure to 
advertising can increase the perceived ease of retrieving positive 
attributes of a product (Menon and Raghubir, 2003) or their own 
cognitive responses to an advertisement for it (Tybout et al., 2005), 
influencing evaluations of the product. 
This study is based on the assumption that DTC advertising for 
antidepressant brands can be a source of accessible information that is 
stored in consumers’ memory and influences their estimates of the 
prevalence and lifetime risk of depression. An (2007) finds consumers’ 
unaided recall of print DTC antidepressant advertisements positively 
predicts their perceived prevalence of depression. The study did not 
control for interpersonal experiences with depression, while social 
cognition researchers (Higgins and King, 1981; Shrum and Bischak, 
2001; Wyer and Shrull, 1989) point out various modes of experiences 
with a social phenomenon have influences on the perceived social 
reality of the phenomenon. An (2007) also did not test the relationship 
between recall and consumers’ own perceived lifetime risk of 
depression. 
Building on An (2007) and the studies in the past that exhibit a 
relationship between media exposure and higher prevalence and risk 
perceptions, we hypothesize that, after controlling for interpersonal 
experiences with depression, the more familiar consumers are with 
DTC advertisements for antidepressants, the more prevalent they will 
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perceive clinical depression to be in the U.S. (H1), and the higher they 
will perceive their own lifetime risk of depression to be (H2). We assert 
familiarity is a more appropriate independent variable than recall to 
predict social cognition, because recall requires active and intensive 
information processing, while social judgments driven by availability 
heuristic can be formed and retrieved through semi-conscious, 
automatic information processing (Menon and Raghubir, 2003). In 
fact, in An's (2007) study, 65% of survey respondents did not recall 
any advertised antidepressant brand, and 25% recalled just one of the 
five advertised brands. Familiarity can be retrieved and influence 
judgments in a low-involvement, semiconscious manner (Hawkins and 
Hoch, 1992). 
Mass media are not the only information source to influence 
consumers’ perceived social reality of depression. Individuals are 
embedded in different life patterns and socio-cultural contexts, which 
present alternative sources of retrievable information and therefore 
can influence their perceptions of the prevalence and risk of 
depression independent of the influences from mass media. Such 
alternative information sources include memory of personal 
experiences and interpersonal experiences, such as word-of-mouth 
(Shrum and Bischak, 2001, p. 187). Higgins and King (1981) and 
Wyer and Srull (1989) suggest information attained through personal 
experiences is highly accessible when people think about a real-world 
prevalence of a phenomenon related to such experiences. 
We expect interpersonal experiences with depression, 
conceptualized as knowing personally meaningful others (e.g. family 
members, relatives and close friends) who suffer from clinical 
depression and seek professional help, will also present a source of 
accessible information when individuals report their perceptions of 
depression, especially for those who have not experienced clinical 
depression. Therefore, it is hypothesized that the more interpersonal 
experiences individuals have with depression, the more prevalent they 
will perceive clinical depression to be (H3) and the higher they will 
perceive their own lifetime risk of depression to be (H4). This study 
does not incorporate the role played by direct, personal experiences 
with depression, because the overwhelming majority of study subjects 
have not experienced clinical depression. Subjects who reported 
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personal experiences with clinical depression were deleted from data 
analysis. 
Method 
Subjects and procedure 
A survey was conducted with a convenience sample of 221 
undergraduates enrolled in introductory advertising courses at a large 
state university in the U.S. Of the subjects, 68.2% were females. 
Subjects ranged in age from 17 to 27 (M = 20.01, SD = 1.29). The 
majority were whites (71.9%), followed by Hispanics (17.6%), 
African–Americans (4.1%), and Asian–Americans (3.6%). Subjects 
were largely from middle (29.9%) or upper middle class (54.8%) 
families. Only 2.7% reported they were from working class families. 
Subjects received extra credit for participation. The class 
curriculum did not include topics that could have sensitized subjects to 
the purpose of this study. Survey instruments were distributed in 
class, but subjects completed them in private at home. Though less 
preferable than a random sample from the general population, 
undergraduates form a solid sample for this study, because consumer 
socialization and expressions of social reality begin at early life stages 
(John, 1999; Singh et al., 2003), and depression is increasingly 
prevalent among young adults (Kessler et al., 2001). However, 
homogeneity of the sample might yield results different from those 
found in the general population. Therefore, one should take caution 
when interpreting ﬁndings of this study. 
The instrument 
To help subjects differentiate clinical depression, which is the 
focus of this study, from short periods of sadness, the cover sheet 
explicitly stated, “depression is defined in this project as a form of 
medical illness, or a state of sadness that has reached the point of 
persistently disrupting a person’s social functioning and daily 
activities.” In addition, for comparability of subjects’ responses with 
nation-wide epidemiological data for depression, (Kessler et al., 1994; 
National Comorbidity Survey, 2003; Regier et al., 1993), the cover 
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sheet further emphasized that we defined “adults” as “American men 
and women of 18 and over.” 
Besides the dependent and independent variables, the 
instrument measured a few control variables, such as socio-economic 
status (SES), gender and interest in DTC advertising, which likely have 
external influences on the relationships we hypothesized. For example, 
SES is reported to be associated with media use patterns (Condry, 
1989) and an increased risk of depression (Gilman et al., 2003). SES 
may also influence consumers’ perceptions of social reality (Hawkins 
and Pingree, 1980; Stroman and Seltzer, 1985). Women’s lifetime risk 
of depression is twice as high as that of men (Kornstein and Wojcik, 
2002), which may influence their perceived social reality of depression. 
At the same time, women’s media use patterns differ from men’s in a 
way that can influence their perception of depression. For example, 
Reader’s Digest is a popular vehicle for DTC advertising with its 
subscription rate being the second highest in the U.S., and its 
readership is skewed towards women (MediaMark, 2002). 
In addition, the assumed causal interpretation for the 
relationships between familiarity with DTC advertisements and 
consumers’ social reality perceptions is that DTC advertising influences 
perceptions, rather than the other way around. A viable alternative 
interpretation will be that those who have inflated perception of 
depression may be interested in DTC advertising, and then become 
more familiar with DTC antidepressant advertisements. The design of 
this study significantly reduces this possibility by controlling the 
interest for DTC advertising. 
However a survey design cannot control all sources of external 
influences. Therefore, one should be cautious in making causal 
interpretations for the findings generated by this design.  
Measures 
Interest in DTC advertising 
Subjects reported their interest in DTC advertising on a seven-
point scale (1 = not at all interested, 7 = extremely interested). On 
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the average, responses were below the mid-point (M = 2.61, SD = 
1.40). 
Interpersonal experiences 
Subjects checked “yes,” “no,” or “don't know” for each of the 
three items asking if they know of someone among their significant 
others, namely family members, relatives and friends, who have 
suffered from depression, sought professional help to deal with it or 
taken an antidepressant. A total of 132 subjects reported that they 
knew of their significant others who suffered from depression, followed 
by 128 subjects reporting they knew of someone who took 
antidepressants. A total of 99 reported they knew of someone who 
sought professional help to deal with depression. As the items were 
internally consistent (α = .82), they were averaged to create a single 
index score. 
Familiarity with DTC advertisements for 
antidepressants 
The survey included six print advertisements for five brands of 
antidepressants, including Prozac, Zoloft, Paxil CR, Wellbutrin XL, and 
Effxor XR. The advertisements were all retrieved from 1997 to 2005 
issues of Reader’s Digest. Except for Paxil CR, which was represented 
by two advertisements, each brand was represented by one 
advertisement. Two ads were used for Paxil CR because 
advertisements for the brand exhibited considerable variations in 
terms of overall themes and execution styles, compared to other 
brands containing only minor variations. Subjects reported how 
familiar they were with each of the six print advertisements on a 
seven-point scale (1 = not at all familiar, 7 = extremely familiar). The 
items exhibited sufficient internal consistency (α = .76), with a mean 
of 2.46 (SD = 1.09). To minimize the risk of test effects, we measured 
familiarity after prevalence and risk perceptions were measured. 
Perceived lifetime risk of depression 
Subjects reported in percentage the chances that they will suffer 
from depression at some point during their lifetime. Female subjects 
on the average perceived their lifetime risk to be 29.09% (SD = 
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27.62), while males perceived the risk to be 31.33% (SD = 33.25). It 
was notable that the two groups did not significantly differ in their 
perception, considering that epidemiological studies indicate the risk is 
20–25% for women and approximately 13% for men (Kessler, 1993, 
1994; NCS, 2003). Therefore, male subjects had more inflated 
perceptions of their lifetime risk of depression compared to women. 
Perceived prevalence of depression 
A composite measure of perceived prevalence of depression was 
constructed by selecting and modifying six social reality measurement 
items from the cultivation theory literature (O'Guinn and Shrum, 1997; 
Shapiro, 1991; Shrum, 1996). Subjects reported in percentage their 
“gut-level” estimates of the probability of the following particular 
situations occurring in the U.S. 
(Q1) In a typical year, what percentage of American adults will 
suffer from depression? 
(Q2) In a typical year, what percentage of American households 
will have one or two members who suffer from 
depression? 
(Q3) In a typical year, what percentage of people with mental 
illnesses will be categorized as depressive patients? 
(Q4) In a typical year, what percentage of male adults will 
suffer from depression in the US? 
(Q5) In a typical year, what percentage of female adults will 
suffer from depression in the US? 
(Q6) In a typical year, what percentage of Americans will have 
one or two family members, relatives or close friends who 
suffer from depression? 
The six items exhibited high internal consistency (α = .86), and 
were averaged to create a single index score. Subjects’ overall 
estimate ranged from 7.17 to 77.50 out of 100 in total (M = 38.01, SD 
= 15.68). On the whole, subjects had inflated perceptions about the 
prevalence of depression. For example, male subjects reported on the 
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average that in a typical year, 28.09% (SD = 17.31) of male adults 
and 35.56% (SD = 18.69) of female adults would experience clinical 
depression in the U.S. Female subjects replied that 26.50% (SD = 
14.04) of male adults and 35.52% (SD = 18.17) of female adults 
would undergo depression in a typical year. It was notable that male 
and female subjects equally overestimated the prevalence of 
depression among male and female adults, because epidemiological 
data indicate that about 9.5% of adults, 12% of female adults and 7% 
of male adults in the U.S. suffer from clinical depression in any given 
year (Regier et. al., 1993). A more recent study reveals 6.5% of 
adults, 8.5% of female adults, and 4.7% of male adults reported that 
they had experienced depression within the last 12–month period 
before the survey was conducted (NCS, 2003). 
Results 
Zero-order correlations 
As a preliminary analysis, zero-order correlations among all the 
variables were run. Missing data were accounted for by list-wise 
deletions. Table I shows that significant correlations were found among 
some of the variables. Especially, a control variable, interest in DTC 
advertising, was significantly associated with interpersonal experiences 
with depression (r = .17, p < .05), familiarity with DTC advertisements 
for antidepressants (r = .29, p < .001) and perceived lifetime risk of 
depression (r = .16, p < .05), suggesting the variable could have had 
external influences had it been not controlled for. There were no 
moderate to strong associations among control and independent 
variables, suggesting the models does not have a multicollinearity 
problem. 
Testing the hypotheses 
Hypotheses 1 & 3 
 A hierarchical multiple regression model was built to test H1 & 
H3, with list-wise deletions accounting for missing data. Gender, age, 
ethnicity and SES were entered as the first step. Because ethnicity was 
a nominal variable with five response categories, it was recoded into 
four dummy variables, each representing one ethnic category. Interest 
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in DTC advertising was entered as the second step, followed by 
interpersonal experiences as the third step and familiarity with DTC 
antidepressant advertisements as the fourth step. The dependent 
variable was perceived prevalence of depression in the U.S. 
H1 predicted that college students’ familiarity with DTC 
advertisements for antidepressant brands would be positively 
associated with perceived prevalence of depression in the U.S. The 
results supported this prediction in the complete model (β = .18, p < 
.02) (see Table II). H3 predicted that college students’ interpersonal 
experiences with depression would be positively associated with 
perceived prevalence. H3 was not supported. The coefficient for 
interpersonal experiences was positive but did not reach statistical 
significance (β = .11, p > .13) (see Table II). Familiarity with 
advertisements explained 2.60% of the variances in perceived 
prevalence of depression [F(1, 195) = 5.49, p < .02]. 
Hypotheses 2 & 4 
A hierarchical multiple regression model was built to test H2 and 
H4. The model was the same as the one used to test H1 and H3, 
except that the dependent variable was perceived lifetime risk of 
depression. 
H2 predicted that familiarity with DTC advertisements for 
antidepressants would be positively associated with perceived lifetime 
risk of depression. This hypothesis was supported in the complete 
model (β = .20, p < .01) (see Table III). H4 predicted that college 
students’ interpersonal experiences with depression would be 
positively associated with perceived lifetime depression risk. The 
results also supported this prediction (β = .19, p < .01) (see Table 
III), although the relationship became weaker than the zero-order 
correlation (r = .23, p < .01) it had with perceived depression risk 
(see Table I). Together, the two independent variables explained 
7.30% of the variances in perceived lifetime depression risk [F(2, 194) 
= 7.95, p < .001]. 
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Based on the research traditions of cultivation theory, construct 
accessibility and availability heuristic, this study finds that familiarity 
with DTC print advertisements for antidepressant brands are positively 
associated with perceptions of the prevalence and lifetime risk of 
depression. Interpersonal experiences with depression, defined as the 
awareness that their meaningful others have suffered from depression, 
sought professional help, or taken antidepressant medication, 
significantly predict perceived lifetime risk, but not perceived 
prevalence of depression. 
These findings suggest significant implications in terms of 
marketing strategy, public health and the business ethics of 
pharmaceutical advertising. We begin with the strategic marketing 
implications. Putsis and Dhar (2001) suggest brand promotions 
produce expansion of a new product category, in addition to brand 
switching. This suggests promotions are not necessarily a zero-sum 
game (Putsis and Dhar, 2001). Donohue and Berndt (2004) find DTC 
advertising for antidepressants increases the number of prescriptions 
for antidepressants, implying DTC advertising has potentiality to 
expand the market of antidepressants. The findings of the current 
study imply DTC advertising’s category expanding effect may occur 
because consumers become familiar with DTC advertisements for 
antidepressants, and the subjective judgment of familiarity potentially 
leads them to perceive depression as more prevalent in the US and 
estimate their own lifetime depression risk to be higher. Research on 
health behavior shows consumers’ risk assessment of a health problem 
may produce attitudinal and behavioral changes, such as engaging in 
preventive and remedial behaviors (Block and Keller, 1998; Irwin et 
al., 1996; Raghubir and Menon 1998; Siegel et al., 1998), including 
consultation with doctors. Therefore, changes in risk perception 
triggered by DTC advertising may drive consumers to visit doctors’ 
offices to discuss depression and/or request antidepressant treatment. 
Considering that limited market size is one of the major reasons 
that the introduction of a new product fails, when launching a new 
drug category, the findings of this study imply pharmaceutical 
companies may consider using marketing tools to make consumers 
more aware of the prevalence and risk of the relevant disease 
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category in addition to showing the drug’s competitive advantages. As 
consumers become gradually more familiar with the disease category, 
more emphasis may be placed on product differentiation, or points of 
difference between brands in a drug category. This cycle appears to 
characterize DTC advertising campaigns for antidepressants, as 
campaigns for early market leaders, such as Prozac and Zoloft, 
conveyed the message that clinical depression is common, while 
campaigns for brands launched at a later stage emphasized points of 
difference. For example, Paxil CR was positioned as a social anxiety 
disorder treatment, while Wellbutrin XL was positioned as the first 
antidepressant without sexual side effects. Unlike Prozac and Zoloft, all 
DTC advertisements for Effexor XR and Wellbutrin XL feature female 
models, implying the two brands are targeted at women. 
The findings also have implications for public health. If DTC 
advertising potentially influences consumers’ perceptions of the social 
reality of depression, as the findings suggest, what impact will the 
phenomenon have on consumer health? To that end, we suggest the 
following three hypothetical situations to further conceptualize how 
cultivation effects may have occurred in this study. 
Situation 1: Consumers may largely have underrated 
perceptions about the social reality of depression, and cultivation 
effects lead them to have more realistic prevalence and risk 
perceptions. 
Situation 2: Consumers may largely have overrated perceptions 
about the social reality of depression, and cultivation effects lead them 
to have further inflated prevalence and risk perceptions. 
Situation 3: Consumers may have perceptions more or less 
evenly split around the figures presented by the epidemiological data, 
and cultivation effects may only occur in a group with underrated or 
overrated perceptions. 
Cultivation effects are a positive social phenomenon in the first 
situation, whereas the second situation indicates a negative 
phenomenon. The third presents a more complex picture. 
Regarding subjects’ perceptions of the prevalence of depression, 
data for this study generally support the second scenario, because on 
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the average subjects reported about 38% (SD = 18.01) of adults 
experience clinical depression each year, whereas epidemiological 
studies indicate that about 10% experience it (Regier et al., 1993). On 
the other hand, regarding the perceived lifetime risk of depression, 
male subjects reported that their risk would be 32% (SD = 33.29), 
whereas females perceived it to be 29% (SD = 28.05). Epidemiological 
studies suggest that the lifetime risk of depression is approximately 
13% for men and 20–25% for women (Kessler, 1993, 1994; NCS, 
2003). 
Interestingly, females had fairly realistic risk perceptions while 
males were largely unrealistic. When multiple regressions were 
conducted separately for men (n = 70) and women (n = 151), the 
coefficient for familiarity with antidepressant advertisements was .34 
(r < .013) for men and .18 (r < .049) for women. This shows 
cultivation effects regarding lifetime risk perception occurs more 
strongly among men, who already have inflated perceptions, than 
among women. Given that depression has been a largely under-
diagnosed and stigmatized disease, leading consumers to have further 
inflated risk perceptions may have positive behavioral consequences, 
such as encouraging depressed people to visit a doctor’s office and 
leading consumers to comply better with antidepressant medication 
(Donohue et al., 2004). However, it may also have negative behavioral 
influences, such as leading consumers to make unnecessary visits to 
the doctor’s office and therefore driving up health costs (Findlay, 
2001). Research may be conducted to further explore the behavioral 
consequences of the cultivation effects observed in the current study. 
The findings of this study also have implications for the business 
ethics of pharmaceutical advertising. Public criticism is mounting 
against DTC advertising, as opponents contend that consumers are 
misled by DTC advertising. At FDA hearings they suggested the 
possibility of placing a ban or moratorium on DTC advertising. To 
defend DTC advertising, GSK sent 8,000 sales representatives out to 
manage the public policy issue in its favor (Thomaselli, 2006). The 
pharmaceutical industry’s professional association, the Pharmaceutical 
Research Manufacturers of America (PhRMA), has been strong 
proponents of DTC advertising. To that end, in August 2005, PhRMA 
introduced codes of conduct aimed at providing advertisers with 
guideline for DTC advertising (PhRMA, 2005, see Appendix A). 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Business Ethics, Vol. 79, No. 4 (2008): pg. 379-393. DOI. This article is © Springer and permission has been 
granted for this version to appear in e-Publications@Marquette. Springer does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Springer. 
18 
 
What are the potential implications of PhRMA's principles for the 
ethics of pharmaceutical advertising, especially regarding the research 
findings of this study? The preamble to the principles states that a 
“strong empirical record demonstrates that DTC communications about 
prescription medicines serve the public health” by increasing 
awareness of diseases (PhRMA, 2005). Therefore, PhRMA encourages 
drug companies to promote disease awareness through DTC 
advertising (see Principle 9 in Appendix A). However, none of the 
principles refers to the possibility that becoming familiar with DTC 
advertising for a disease category may result in leading consumes to 
have overrated perceptions of the risk of the disease. This deletion 
may be a potential threat to public health, especially when one 
considers the research finding that the association between familiarity 
with DTC antidepressant advertising and perceived risk of depression 
was stronger among those, mostly consisting of male subjects, who 
already have unrealistically high risk perceptions of depression. 
PhRMA (2005) also emphasizes DTC advertising should be 
designed to “responsibly educate the consumer about that medicine, 
and, where appropriate, the condition for which it may be prescribed.” 
Given risk perception’s potentiality to produce behavioral 
consequences (Block and Keller, 1998; Irwin et al., 1996; Raghubir 
and Menon, 1998; Siegel et al., 1998), PhRMA may consider 
encouraging drug companies to include in DTC advertising information 
on the prevalence and risk of developing the relevant disease. Such an 
initiative will increase the educational value of DTC advertising, with 
higher potentiality to “responsibly” increase consumers’ awareness 
about diseases and medicine and discourage them from having 
unrealistic perceptions about their vulnerability to the diseases. We 
argue the PhRMA guideline will help solidify the business ethics of DTC 
advertising and gain the public’s confidence in the value of the new 
business practice only if it presents such specific and concrete 
principles to pharmaceutical companies. 
Limitations and further suggestions 
The current study has a number of conceptual and 
methodological limitations. First, although we alluded to causal 
interpretations of data driven by the perspectives of cultivation theory 
and availability heuristic, correlational data cannot establish causality. 
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Therefore, the findings and their implications for pharmaceutical 
marketing strategy, consumer health and business ethics should be 
interpreted with caution. A further study with an experimental design 
will generate data that allow solid causal interpretations. Equally 
important, findings of this study relate specifically to DTC print 
advertising for antidepressants. Future studies may augment the 
external validity by incorporating both print and broadcast media, 
because DTC advertising is frequently conducted through broadcast 
media (Rosenthal et al., 2002) and consumers’ processing of 
information in electronic media may be different from that in print 
media. In addition, although this study is framed around an early age 
group at which individuals form perceptions about diseases, it will be 
interesting to explore how the theoretical perspectives apply to the 
general population. It should also be noted that this study is based on 
a convenience sample. Therefore the data do not provide conclusive 
evidence for the research findings. Insightful as they are, we suggest 
researchers replicate the research findings with a nationally 
representative sample. Last, although cultivation theory does not 
suggest a causal link between prevalence and risk perceptions, 
Kalichman and Cain (2005) reveal that prevalence perceptions may 
increase perceptions of risk. Therefore, one may organize a study to 
construct and test a model of simultaneous interrelationships among 
the key concepts discussed in the current project. 
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Table I  Zero-order correlations 
 *p < .05 (2-tailed), **p < .01 (2-tailed). 
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PhRMA's guiding principles for direct-to-consumer advertising 
To express the commitment of PhRMA members to deliver DTC 
communications that serve as valuable contributors to public health, PhRMA 
has established the following voluntary guiding principles. 
Principle 1. 
These Principles are premised on the recognition that DTC advertising 
of prescription medicines can benefit the public health by increasing 
awareness about diseases, educating patients about treatment options, 
motivating patients to contact their physicians and engage in a dialogue about 
health concerns, increasing the likelihood that patients will receive 
appropriate care for conditions that are frequently under-diagnosed and 
under-treated, and encouraging compliance with prescription drug treatment 
regimens. 
Principle 2. 
In accordance with FDA regulations, all DTC information should be 
accurate and not misleading, should make claims only when supported by 
substantial evidence, should reflect balance between risks and benefits, and 
should be consistent with FDA approved labeling.  
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DTC television and print advertising which is designed to market a 
prescription drug should also be designed to responsibly educate the 
consumer about that medicine and, where appropriate, the condition for 
which it may be prescribed. 
Principle 4. 
DTC television and print advertising of prescription drugs should 
clearly indicate that the medicine is a prescription drug to distinguish such 
advertising from other advertising for nonprescription products. 
Principle 5. 
DTC television and print advertising should foster responsible 
communications between patients and health care professionals to help 
patients achieve better health and a more complete appreciation of both the 




In order to foster responsible communication between patients and 
health care professionals, companies should spend an appropriate amount of 
time to educate health professionals about a new medicine or a new 
therapeutic indication before commencing the first DTC advertising campaign. 
In determining what constitutes an appropriate time, companies should take 
into account the relative importance of informing patients of the availability of 
a new medicine, the complexity of the risk-benefit profile of that new 
medicine and health care professionals’ knowledge of the condition being 
treated. Companies should continue to educate health care professionals as 
additional valid information about a new medicine is obtained from all reliable 
sources. 
Principle 7. 
Working with the FDA, companies should continue to responsibly alter 
or discontinue a DTC advertising campaign should new and reliable 
information indicate a serious previously unknown safety risk. 
Principle 8. 
Companies should submit all new DTC television advertisements to the 
FDA before releasing these advertisements for broadcast. 
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DTC television and print advertising should include information about 
the availability of other options such as diet and lifestyle changes where 
appropriate for the advertised condition. 
Principle 10. 
DTC television advertising that identifies a product by name should 
clearly state the health conditions for which the medicine is approved and the 
major risks associated with the medicine being advertised. 
Principle 11. 
DTC television and print advertising should be designed to achieve a 
balanced presentation of both the benefits and the risks associated with the 
advertised prescription medicine. Specifically, risks and safety information in 
DTC television advertising should be presented in clear, understandable 
language, without distraction from the content, and in a manner that supports 
the responsible dialogue between patients and health care professionals. 
Principle 12. 
All DTC advertising should respect the seriousness of the health 
conditions and the medicine being advertised. 
Principle 13. 
In terms of content and placement, DTC television and print 
advertisements should be targeted to avoid audiences that are not age 
appropriate for the messages involved. 
Principle 14. 
Companies are encouraged to promote health and disease awareness 
as part of their DTC advertising. 
Principle 15. 
Companies are encouraged to include information in all DTC 
advertising, where feasible, about help for the uninsured and underinsured. 
 
